ArticleCancers2025
Ten Years of Euromelanoma in Hungary: Nationwide Trends and Risk Factors for Skin Cancer in Central-Eastern Europe.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesLarge-scale, country-specific data on skin cancer predictors are scarce in Hungary. The Euromelanoma campaign offers a decade-long opportunity to investigate constitutional, behavioral, and motivational risk factors in a Central European setting through a national cross-sectional analysis.
methodsBetween 2009 and 2018, Hungarian participants underwent dermatological screening. Diagnoses of clinically suspicious skin cancers were based on dermoscopic assessment, as histopathological confirmation was not systematically available. Among 18,598 standardized surveys, logistic regression identified independent predictors of clinically suspicious skin cancers overall and separately for melanoma and non-melanoma skin cancers (NMSCs).
resultsClinically suspicious skin cancers were detected in 3.9% of participants (1.7% melanoma, 2.3% NMSC). Strong predictors across all cancer types were atypical nevi (OR 4.75), personal history of NMSC (OR 3.42), and melanoma (OR 1.99). For melanoma, atypical nevi (OR 13.12), prior melanoma (OR 5.95), heavy sunbed use (OR 2.15), and trunk lentigines (OR 1.47) were significant. For NMSC, age (OR 1.08 per year), personal history of NMSC (OR 4.75), family history of melanoma (OR 2.41), and atypical nevi (OR 1.76) were dominant. Screening motivation influenced detection: participants attending for a changing lesion had higher odds of suspicious findings, whereas those attending for routine checks, family/friend history, or "many moles" had lower odds.
conclusionsOver a decade of Euromelanoma screening, atypical nevi, prior skin cancer history, and heavy sunbed use emerged as the strongest predictors of suspicious skin cancers. Participant motivation shaped detection patterns, supporting risk-stratified screening, targeted public education, and stricter regulation of artificial ultraviolet exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.